Sindrome.del.Ovario.Poliquistico

Insulinosensibilizantes 125
Co-administration of metformin during
rFSH treatment in patients with clomiphene
citrate-resistant polycystic ovarian
syndrome: a prospective randomized
trial. Hum Reprod. 2002;17:289-94.
16
Kjøtrod SB, Von During V, Carlsen SM.
Metformin treatment before IVF/ICSI
in women with polycystic ovary syndrome;
a prospective, randomized, double
blind study. Hum Reprod. 2004;19:
1315-22.
17
George SS, George K, Irwin Ch, Job
V, Selvakumar R, Jeyaseelan V, et al.
Sequential treatment of metformin and
clomiphene citrate in clomiphene-resistant
women with polycystic ovary syndrome:
a randomized, controlled trial.
Hum Reprod. 2003;18:299-304.
18
Elter K, Imir G, Durmusglu F. Clinical,
endocrine and metabolic effects of metformin
added to ethinyl estradiol-cyproterone
acetate in non-obese women with
polycystic ovarian syndrome: a randomized
controlled study. Hum Reprod.
2002;17:1729-37.
19
Ibáñez L, Zegher F. Low-dose combination
of flutamide, contraceptive for
non-obese, young ovary syndrome. Hum
Reprod. 2003;18:57-60.
20
Glueck Ch, Phillips H, Cameron D,
Sieve-Smith L, Wang P. Continuing metformin
throughout pregnancy in women
with polycystic ovary syndrome appears
to safely reduce first-trimester spontaneous
abortion: a pilot study. Fertil Steril.
2001;75:46-52.
21
Glueck Ch, Wang P, Kobayashi S, Phillips
H, Sieve-Smith L. Metformin therapy
throughout pregnancy reduces the
development of gestational diabetes in
women with polycystic ovary syndrome.
Fertil Steril. 2002;77:520-5.
22
Glueck CJ, Goldenberg N, Pranikoff
J, Loftspring M, Sieve L, Wang P.
Height, weight and motor-social development
during the first months of life
in 126 infants born to 109 mothers
with polycystic ovary syndrome who
conceived on an continued metformin
through pregnancy. Hum Reprod. 2004;
19:1323-30.
23
Rang HP, Dale MM. Farmacología. Churchill
Communications Europe España:
Churchill Livingstone; 1995.
24
Garber AJ, Duncan TG, Goodman AM,
et al. Efficacy of metformin in type II
diabetes: results of a double-blind, placebo-controlled,
dose-response trial. Am
J Med. 1997;102:491-7.
25
Hundal RS, Krssak M, Dufour S, et
al. Mechanism by which metformin
reduces glucose production in type 2
diabetes. Diabetes. 2000;49:2063-9.
26
Domínguez LJ, Davidoff AJ, Srinivas PR,
et al. Effects of metformin on tyrosine
Kinase activity, glucosa traansport, and
intracellular calcium in rat vascular
smooth muscle. Endocrinology. 1996;
137:113-21.
27
Large V, Beylot M. Modifications of citric
acid cycle activity and gluconeogenesis
in streptozocin-induced diabetes and
effects of metformin. Diabetes. 1999;48:
1251-7.
28
Zhou G, Myers R, Li Y, et al. Role of
AMP-activated protein Kinase in the
mechanism of metformin action. J Clin
Invest. 2001;108:1167-74.
29
Argaud D, Roth H, Wiernsperger N, et
al. Metformin decreases gluconeogenesis
by enhancing the pyruvate kinase
flux in isolated rat hepatocytes. Eur J
Biochem. 1993;213:1341-8.
30
Mamputu JC, Wiernsperger NF, Renier
G. Antiatherogenic properties of metformin;
the experimental evidence. Diabetes
Metab. 2003 Sep;29(4 pt 2):6S71-6.
31
Turner RC, Cull CA, Frighi V, et al. Glycemic
control with diet, sulfonylurea,
metformin, or insulin in patients with
type 2 diabetes mellitus: progressive
requirements for multiple therapies
(UKPDS 49). UK Prospective Diabetes
Study (UKPDS) Group. JAMA. 1999;281:
2005-12.
32
Landin K, Tengborn L, Smith U. Treating
insulin resistance in hypertension with